Tremfya beats Cosentyx in head-to-head plaque psoriasis study

Johnson & Johnson (NYSE: JNJ) has announced positive data from the Phase III ECLIPSE study showing that Tremfya (guselkumab) was superior to Novartis’ (NOVN: VX) Cosentyx (secukinumab) in moderate to severe plaque psoriasis.

The results show that, for the primary endpoint assessed at week 48, 84.5% of patients treated with the interleukin (IL)-23 blocker Tremfya, developed by J&J’s pharmaceuticals arm Janssen, achieved at least 90% improvement.

Those treated with Cosentyx, an IL-17 inhibitor, achieved a 70% rate of skin clearance, according to a commonly-used scale.